Abstract
The accumulation of toxic products (TP) of the processing of the amyloid precursor protein is the likely initial event in a “cascade of events” that leads to Alzheimer's disease (AD). The immune system is, however, attracting the increasing attention of researchers working in this area. First, as a responder to and possible contributor to the pathological events that occur in AD, second as a modifier of the production of and clearance of TP, third as part of a system of neuroprotection, and fourth as a suitable target in designing AD treatment strategies. While still at an early stage of understanding these complex, multidimensional, and at times, conflicting roles of the immune system in AD it is likely that successful AD treatment strategies will need to carefully consider and account for the immune network within the overall design.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
